Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Brightling

Showing results (1-10 of 75) with videos related to

Pageof 8
Sort By:
Recent Patents on Inflammation & Allergy Drug Discovery|September 3, 2010
TNF-alpha antagonism in severe asthma?Dhananjay Desai, Christopher Brightling
Expert Review of Respiratory Medicine|April 9, 2016
Mepolizumab for the reduction of exacerbations in severe eosinophilic asthmaRichard Russell, Christopher Brightling
Chest|February 9, 2012
OX40/OX40 ligand interactions in T-cell regulation and asthmaDavinder Kaur, Christopher Brightling
Advances in Clinical Chemistry|August 9, 2012
Cytokines and cytokine-specific therapy in asthmaDhananjay Desai, Christopher Brightling
American Journal of Respiratory and Critical Care Medicine|August 25, 2009
Magic bullets: the new goal for asthmaSalman Siddiqui, Christopher Brightling
The European Respiratory Journal|May 11, 2019
Airway inflammation in COPD: progress to precision medicineChristopher Brightling, Neil Greening
The World Allergy Organization Journal|November 16, 2013
Section 3. A discussion of flexible dosing and patient-centered therapy: highlights of the asthma summit 2009: beyond the guidelinesG Walter Canonica, Christopher Brightling
Clinical Science (London, England : 1979)|July 2, 2017
Pathogenesis of asthma: implications for precision medicineRichard J Russell, Christopher Brightling
Current Opinion in Pulmonary Medicine|November 4, 2010
Can inhaled corticosteroids prevent asthma exacerbations?Dhananjay Desai, Salman Siddiqui, Christopher Brightling
Expert Opinion on Investigational Drugs|January 25, 2018
Fevipiprant in the treatment of asthmaChristobelle White, Adam Wright, Christopher Brightling
Pageof 8

Showing results (1-10 of 75) with videos related to

Sort By:
Pageof 8
Recent Patents on Inflammation & Allergy Drug Discovery|September 3, 2010
TNF-alpha antagonism in severe asthma?Dhananjay Desai, Christopher Brightling
Expert Review of Respiratory Medicine|April 9, 2016
Mepolizumab for the reduction of exacerbations in severe eosinophilic asthmaRichard Russell, Christopher Brightling
Chest|February 9, 2012
OX40/OX40 ligand interactions in T-cell regulation and asthmaDavinder Kaur, Christopher Brightling
Advances in Clinical Chemistry|August 9, 2012
Cytokines and cytokine-specific therapy in asthmaDhananjay Desai, Christopher Brightling
American Journal of Respiratory and Critical Care Medicine|August 25, 2009
Magic bullets: the new goal for asthmaSalman Siddiqui, Christopher Brightling
The European Respiratory Journal|May 11, 2019
Airway inflammation in COPD: progress to precision medicineChristopher Brightling, Neil Greening
The World Allergy Organization Journal|November 16, 2013
Section 3. A discussion of flexible dosing and patient-centered therapy: highlights of the asthma summit 2009: beyond the guidelinesG Walter Canonica, Christopher Brightling
Clinical Science (London, England : 1979)|July 2, 2017
Pathogenesis of asthma: implications for precision medicineRichard J Russell, Christopher Brightling
Current Opinion in Pulmonary Medicine|November 4, 2010
Can inhaled corticosteroids prevent asthma exacerbations?Dhananjay Desai, Salman Siddiqui, Christopher Brightling
Expert Opinion on Investigational Drugs|January 25, 2018
Fevipiprant in the treatment of asthmaChristobelle White, Adam Wright, Christopher Brightling
Pageof 8